GLP-1 Drugs, Obesity & Surgical Infection Risk What the 2026 Evidence Means for IPC HOSPITAL INFECTION CONTROL TIP OF THE DAY 027 GLP-1 Drugs, Obesity & Surgical Infection Risk What the 2026 Evidence Means for IPC 1 WHY IT MATTERS 2026 is the year GLP-1 receptor agonists went mainstream globally oral semaglutide approved by FDA in December 2025, tirzepatide expanding indications, Indian patent expiries imminent, and one in eight adults now on a GLP-1 medication in some markets
However, it is not meant for the treatment of type 1 diabetes or diabetic ketoacidosis in adults
Anti-aging properties: GH doesnt just help build muscles, but all kinds of proteins in the body, including collagen
We next analyzed the time spent in the center zone and the peripheral zone in the OFT and observed that Ex-4 produced anxiogenic effects in SPF mice, while Ex(9-39) had no effect on ABX mice (Supplementary Fig
B4126) was dissolved in oleoylethanolamide (SigmaAldrich, USA